AU2016319107B2 - Methods of treating neurodegenerative disorders in a particular patient population - Google Patents

Methods of treating neurodegenerative disorders in a particular patient population Download PDF

Info

Publication number
AU2016319107B2
AU2016319107B2 AU2016319107A AU2016319107A AU2016319107B2 AU 2016319107 B2 AU2016319107 B2 AU 2016319107B2 AU 2016319107 A AU2016319107 A AU 2016319107A AU 2016319107 A AU2016319107 A AU 2016319107A AU 2016319107 B2 AU2016319107 B2 AU 2016319107B2
Authority
AU
Australia
Prior art keywords
subject
apoe4
score
mmse
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016319107A
Other languages
English (en)
Other versions
AU2016319107A1 (en
Inventor
Susan ABUSHAKRA
John Hey
Petr Kocis
Aidan POWER
Martin TOLAR
Jeremy Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016319107(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of AU2016319107A1 publication Critical patent/AU2016319107A1/en
Application granted granted Critical
Publication of AU2016319107B2 publication Critical patent/AU2016319107B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016319107A 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population Active AU2016319107B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
AU2016319107A1 AU2016319107A1 (en) 2018-03-22
AU2016319107B2 true AU2016319107B2 (en) 2021-02-25

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016319107A Active AU2016319107B2 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN116712423A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (2) RS68293B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (2) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
SI4296670T1 (sl) * 2018-08-01 2026-04-30 Alzheon, Inc. Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) * 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
CA2142300C (en) 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
EP1664601B1 (en) 2003-08-11 2016-10-12 California Institute Of Technology Microfluidic large scale integration
US20060251714A1 (en) * 2005-04-12 2006-11-09 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
NZ723884A (en) 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) * 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALTAGIRONE CARLO ET AL, AGING CLINICAL AND EXPERIMENTAL RESEARCH GERMANY, (2012-12-01), vol. 24, no. 6, doi:10.3275/8585, ISSN 1720-8319, pages 580 - 587 *
PAUL S. AISEN ET AL, ARCHIVES OF MEDICAL SCIENCE, (2011-01-01), vol. 1, doi:10.5114/aoms.2011.20612, ISSN 1734-1922, pages 102 - 111 *
SLEEGERS KRISTEL et al., "The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects", Trends in Genetics, 18 Jan 2010, vol. 26(2), pages 84 - 93 *

Also Published As

Publication number Publication date
EP4275750C0 (en) 2026-05-06
JP7128536B2 (ja) 2022-08-31
DK3347002T3 (da) 2023-08-14
LT3347002T (lt) 2023-09-11
RS68293B1 (en) 2026-07-31
JP6789579B2 (ja) 2020-11-25
EP3347002A4 (en) 2019-04-24
EP3347002A1 (en) 2018-07-18
US20220096406A1 (en) 2022-03-31
CA2997376A1 (en) 2017-03-16
KR102547164B1 (ko) 2023-06-22
SI3347002T1 (sl) 2023-12-29
EP4275750B1 (en) 2026-05-06
PL3347002T3 (pl) 2023-11-13
FI3347002T3 (fi) 2023-08-10
US20230414541A1 (en) 2023-12-28
ES2952727T3 (es) 2023-11-03
CN116712423A (zh) 2023-09-08
HRP20230809T1 (hr) 2023-10-27
RS64481B1 (sr) 2023-09-29
MX392677B (es) 2025-03-24
EP4275750A3 (en) 2024-01-17
JP2020200352A (ja) 2020-12-17
SMT202300250T1 (it) 2023-09-06
EP4275750A2 (en) 2023-11-15
US11191742B2 (en) 2021-12-07
KR20220042480A (ko) 2022-04-05
KR102412997B1 (ko) 2022-06-23
CN108289870A (zh) 2018-07-17
MD3347002T2 (ro) 2023-10-31
HK1257874A1 (en) 2019-11-01
AU2016319107A1 (en) 2018-03-22
MX2022003128A (es) 2022-08-02
JP2025065545A (ja) 2025-04-17
CN116712422A (zh) 2023-09-08
SMT202600257T1 (it) 2026-07-16
EP3347002B1 (en) 2023-06-07
MX2018003023A (es) 2018-06-06
JP2018526407A (ja) 2018-09-13
HUE062511T2 (hu) 2023-11-28
KR20180051561A (ko) 2018-05-16
WO2017044840A1 (en) 2017-03-16
CA2997376C (en) 2024-05-14
JP2022145949A (ja) 2022-10-04
PT3347002T (pt) 2023-07-27

Similar Documents

Publication Publication Date Title
US20230414541A1 (en) Methods of treating neurodegenerative disorders in a particular population
CN109890391B (zh) 痴呆症的治疗
CN103608007A (zh) 用于治疗神经障碍的新组合物
WO2020222799A1 (en) A method of treating mental, behavioral, cognitive disorders
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
HK40056250A (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
AU2019211135A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
WO2018197383A1 (en) Idalopirdine-based combinatorial therapies of alzheimer's disease
HK40003690B (en) Treatment of dementia
HK1224182B (en) Composition comprising torasemide and baclofen for treating neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)